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Effects of FK506 in rat and human resistance arteries. inhibits T-lymphocyte activation. Like cyclosporine, an-
Background. FK506 is widely used in organ transplantation other potent immunosuppressant, FK506, interferes with
and causes hypertension. However, little is known about the intracellular signaling mechanisms in a calcium-depen-impact of the drug on the cardiovascular system.
dent manner, resulting in the inhibition of the transcrip-Methods. We therefore investigated the effect of FK506 on
tion of genes regulating the syntheses of cytokines [1].resistance artery and blood pressure responsiveness to vaso-
constrictors and vasodilators. Studies were conducted in vitro The adverse effects of FK506 are similar to those related
using human and murine resistance artery, ex vivo in resistance to cyclosporine’s use and include hyperglycemia, dyslipi-
artery isolated from rats treated with FK506 (6 mg/kg/day), demia, nephrotoxicity, neurotoxicity, and hypertensionand in vivo in conscious, treated animals.
[2, 3]. However, differences in the intensity and incidenceResults. In vitro exposure (24 hr) of human and rat resistance
of these side effects may exist. For example, hyperten-artery to FK506 (1000 ng/ml) increased the sensitivity to norepi-
nephrine (NE) and impaired the response to acetylcholine sion, which is an important side effect of both drugs, in
(Ach) and sodium nitroprusside (SNp). In contrast, arteries some investigations has been found to be less severe and
isolated from rats given FK506 for eight days showed a reduced
frequent in patients receiving FK506 [4–8]. In their study,sensitivity to NE (P , 0.05) and a normal endothelium-depen-
Canzanello et al observed that hypertension occurreddent relaxation. Their incubation with l-arginine caused a sig-
nificant reduction in Ach sensitivity in the FK506 group (P , in 82% of their liver transplant patients treated with
0.05) but not in controls, suggesting enhancement of nitric cyclosporine and in only 33% of those treated with
oxide production by the drug. The sensitivity to SNp was re- FK506 [9]. Spencer, Goa and Gillis in their recent review,
duced, as in the in vitro experiments (P , 0.05). Rats given
reached a similar conclusion in which the frequency ofFK506 for eight days presented blood pressure similar to that
adverse effects of both immunosuppressive drugs wasin controls but also presented signs of a compensatory response
to excess vasodilation: tachycardia (P , 0.01), reduced blood compared [10]. In particular, the authors reported that
pressure sensitivity to NE and Ach, blunted heart rate response although FK506 was associated with a higher incidence
to both agonists, and exaggerated hypotension at high doses of diabetes mellitus, neurotoxicity, and nephrotoxicity,of Ach. After 21 days of treatment, blood pressure remained
cyclosporine caused more hyperlipidemia, hypertension,similar to that in controls, but resistance artery showed further
hirsutism, and gingival hyperplasia in patients submittedfunctional deterioration, with significant impairment of the
maximum responses to Ach and to SNp. to different modalities of organ transplantation.
Conclusion. FK506 presents significant vascular toxicity af- Intense research has been devoted to the elucidation
fecting mainly smooth muscle relaxation and alters vascular of the pathogenesis of cyclosporine-induced hyperten-hemodynamics. The data suggest that similar cardiovascular
sion. Several studies have now established that the drugchanges may occur in transplant patients and represent the
increases systemic [11], renal [8], and coronary [12] vas-forerunner of hypertension often seen with more prolonged
use of the drug. cular resistance. Others have shown that increased vascu-
lar resistance is a consequence of drug-induced impair-
ment of arterial relaxation. Our own work showed, in
The immunosuppressant agent FK506 (tacrolimus) is particular, that the resistance vessels of rats turned
a macrolide antibiotic of fungal origin that selectively hypertensive by chronic cyclosporine treatment and pre-
sented a pronounced decrease in endothelium-depen-
dent and -independent relaxation associated with re-Key words: vascular tone, hypertension, blood pressure, transplanta-
tion, vasoconstriction, hemodynamics. duction in the sensitivity to vasoconstrictors [13].
Comparatively, there is little information on the vascu-Received for publication April 3, 1998
lar effects of FK506, and the mechanism responsibleand in revised form October 19, 1998
Accepted for publication October 19, 1998 for the hypertensive effect of the drug remains poorly
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although to a lesser degree than cyclosporine [11, 12]. percentage of precontraction with norepinephrine (NE)
However, to our knowledge, no study has been con- for relaxation (100% equals no relaxation). The sensitiv-
ducted to clarify the vascular changes associated with ity to agonists was calculated using computerized nonlin-
FK506 exposure in relation to its hemodynamic effects. ear curve fitting and expressed as the efficient dose induc-
Our goal in this work was therefore to investigate the ing 50% of the maximum response (ED50).
effects of FK506 on blood pressure, blood pressure re-
Experimental protocolssponsiveness, and vascular function, as defined by re-
sponses to vasoconstrictors and vasodilators. Particular Four experimental protocols were performed. Proto-
emphasis was given to the exploration of the functional col 1 aimed to characterize the changes in vascular reac-
alterations in resistance vessels, as small arteries are be- tivity induced by in vitro exposure to FK506. Protocols
lieved to play a central role in the peripheral control 2 through 4 evaluated the effect of chronic short-term
of blood pressure [14]. Most of the experiments were and long-term administration of FK506 in rats on blood
conducted in animals treated with FK506. However, the pressure and on vascular function.
vascular effects of FK506 were also characterized in ani- In protocol 1, human and animal (Sprague-Dawley
mal and human resistance arteries exposed in vitro to rats) arteries were incubated for 24 hours with either
the drug. 1000 ng/ml FK506 (Fujisawa Pharmaceutical Co., Ltd.,
Osaka, Japan) or vehicle (ethanol, 0.1%, vol/vol). Incu-
bation was performed at 378C under a 95% O2 and 5%METHODS
CO2 atmosphere and in Dulbecco’s modified essentialSubjects
medium (DMEM) supplemented with antibiotics (peni-
Small arteries were isolated from fat tissue specimens cillin and streptomycin) and with insulin and transferrin
obtained from seven individuals (3 males and 4 females, [16]. Two arterial segments per animal or per fat biopsy
age 32 to 78 years) during diagnostic procedures per- were prepared and studied simultaneously after incuba-
formed under anesthesia. The protocol was approved tion with either FK506 or vehicle. The following agonists
by the institutional review board. No subject had been were assayed: NE, acetylcholine (Ach), and sodium ni-
exposed to any immunosuppressive drug at the time of troprusside (SNp).
surgery. Arterial segments (approximately 200 mm in In protocol 2, we studied the effects of short-term
diameter and 1 to 3 mm in length) were dissected and (eight days) treatment with FK506 on arterial blood pres-
processed as described later here. sure and vascular function in rats. Two groups of animals
(N 5 11 per group) received either FK506, administeredAnimals
at the dose of 6 mg/kg/day, by gavage, once a day, or theTwelve- to 14-week-old male Sprague-Dawley rats
vehicle for oral formulation (Fujisawa Pharmaceutical).(Charles River Laboratories, Wilmington, MA, USA)
Body weight was recorded daily. Systolic blood pressureswere used for the animal experiments. They were kept
were measured daily at 9:00 a.m. using the tail-cuffon a 12-hour dark–light cycle, with free access to water
method (Narco-Bio, Houston, TX, USA). Animals wereand to standard rat chow (Ralston-Purina Co., St. Louis,
accustomed to blood pressure measurements for oneMO, USA). The animals were housed in metabolic cages
week (baseline) prior the treatment period. For estima-for urine collection as dictated by the protocols.
tion of the effect of FK506 on body weight and blood
pressure, the measurements corresponding to the lastMeasurement of vascular reactivity in resistance
three days of the baseline period were averaged andvessels in the rat
compared with the average weight or blood pressureMesenteric artery resistance vessels were isolated and
corresponding to the last three days of the treatmentprepared as previously described [15]. Briefly, the second
period. The animals were sacrificed in the morning afterbranches of mesenteric arteries were isolated, excised,
a 16- to 18-hour fast. Blood samples were collected forand rinsed with saline. Arterial segments (2 to 3 mm
the determination of the plasma levels of cholesterol,long) were then mounted in a wire myograph and set at
urea, creatinine, calcium, and magnesium. Animals weretheir optimal length for force development by construc-
then killed by decapitation under ether anesthesia, andtion of a length-tension curve. The lumen diameter and
the vascular reactivity of the mesenteric resistance ves-the wall thickness of the arteries were measured first,
sels was studied. The following drugs were assayed inusing a filar micrometer eyepiece. The reactivity to vaso-
sequence: NE, Ach, and SNp. The dose response to Achconstrictors and vasodilators was determined next after
was established first in basal conditions and then after“wake-up” stimulation and a 30-minute equilibration pe-
a 20-minute incubation with 300 mm l-arginine. In ariod in a physiological buffer [16]. Responses were re-
parallel experiment (6 animals per group), we deter-ported as absolute force normalized to axial length of
the vessel (active tension in mN/mm) for contraction or mined glomerular filtration rate (GFR) using 14C-inulin
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[17] at the eighth day of the experiment and measured and unpaired t-tests, or nonparametric tests (Mann–
trough (24-hr postgavage) plasma levels of FK506. Whitney and Wilcoxon’s tests) when appropriate.
Protocol 3 evaluated the effect of short-term (8 days)
treatment with FK506 (6 mg/kg/day) on blood pressure
RESULTSresponsiveness in the rat (N 5 10 animals). The results
Protocol 1were compared with those observed in control rats re-
ceiving the vehicle of the drug. The animals were studied In these experiments, we characterized the direct
conscious, one day after femoral and jugular catheters effect of FK506 on resistance arteries using vessels incu-
were implanted. Basal heart rate and mean arterial pres- bated in vitro with the drug. Initial experiments were
sure (MAP) were determined after a 30-minute infusion conducted with human resistance arteries exposed for
of saline using a direct blood pressure measurement sys- 24 hours to 100 ng/ml FK506. This concentration, which
tem (Kent Scientifics Corp., Litchfield, CT, USA). Blood is close to whole-blood peak concentrations achieved
pressure responsiveness to NE was next determined us- after oral administration in transplant patients [10],
ing bolus injections of NE (0 to 5 mg/kg body wt) in the proved to have no effect on the reactivity to NE, Ach,
jugular vein. Blood pressure and heart rate were allowed
and SNp (data not shown). We thus decided to exposeto return to baseline between each injection (approxi-
the arteries to pharmacological concentrations of FK506mately 5 min). After the last dose of NE, saline was
(1000 ng/ml, that is, approximately 10 to 20 times higherinfused for 20 minutes until the responsiveness to Ach
than therapeutic concentrations). This approach hadwas studied. For this, incremental doses of Ach (0 to 10
been used successfully in previous studies to character-mg/min/300 g body wt) were infused until steady depres-
ize the direct effect of cyclosporine A on vascular func-sion of MAP was observed (approximately 5 min). Each
tion [13].Ach infusion was followed by a 10-minute infusion of
The wall-to-lumen ratio of human vessels exposed tosaline that allowed the return to baseline of both heart
1000 ng/ml FK506 for 24 hours did not differ from con-rate and blood pressure. Dose–response curves were es-
trols (0.094 6 0.007 vs. 0.101 6 0.008, for FK506 andtablished using the peak response for NE or the plateau
control, respectively, P 5 NS). Human arteries exposedresponse for Ach.
in vitro to FK506 showed an increased sensitivity to NEProtocol 4 consisted in repeating the experiments of
[ED50 was 267 6 47 (FK506) and 514 6 146 nm (control,protocol 2 after 21 days of treatment with FK506 (6 mg/
P , 0.01)]; however, the maximum response to NE waskg/day, long term). The animals were housed in meta-
not affected: 2.23 6 0.45 and 2.21 6 0.35 mN/mm forbolic cages for the last 10 days before sacrifice. In the
vessel experiments, incubation with l-arginine was not FK506 and control (P 5 NS). The maximum response
performed. Instead, the Ach dose response was estab- to Ach was slightly but significantly decreased in the
lished first in basal conditions, after incubation with FK506 vessels by comparison to controls (Fig. 1A). The
1025 m indomethacin for 20 minutes and then in the sensitivity to Ach was not affected: 37 6 10 nm and
presence of both indomethacin and 1 mm methylene blue. 79 6 40 nm for control and FK506, respectively (P 5
The response to SNp was studied last. Sodium balance NS). The sensitivity to SNp was significantly reduced, as
was calculated using food consumption and urinary so- indicated by the shift to the right of the SNp dose–
dium excretion determined on samples collected during response curve (Fig. 1B). The maximum response to SNp
the last six days of the treatment period. Blood samples was also impaired, although modestly (same figure).
were obtained for the determination of the plasma levels Similar results were obtained with rat mesenteric ar-
of urea, creatinine, total cholesterol, calcium, magne- teries incubated for 24 hours with 1000 ng/ml FK506.
sium, and trough blood levels of FK506. There was no significant effect of the drug on the wall-
to-lumen ratio of the arteries (not shown) and on theAnalytical methods
maximum response to NE (4.27 6 0.30 vs. 3.98 6 0.22
Urinary sodium was measured by ion selective elec-
mN/mm for FK506 and control, respectively, P 5 NS).trode (E4A; Beckman Instruments Inc., Palo Alto, CA,
However, as observed with human vessels, the sensitivityUSA). Plasma creatinine, urea, total cholesterol, cal-
to NE was increased by FK506: ED50 was 194 6 35 nmcium, and magnesium were measured by spectrophotom-
(FK506) and 296 6 54 nm (controls, P 5 0.015). Theetry using a centrifugal analyzer (Cobas Bio; Roche Di-
maximum response to Ach was minimally but signifi-agnostica, Nutley, NJ, USA). Plasma FK506 levels were
cantly impaired (4.9 6 1.1 vs. 0.8 6 0.7% of precontrac-determined using double-sandwich enzyme-linked im-
tion for FK506 and controls, respectively, P , 0.02), andmunosorbent assay (ELISA; Fujisawa Pharmaceutical).
the sensitivity was reduced: Ach-ED50 was 88 6 20 nm
Statistical analysis (FK506) and 67 6 21 (controls, P , 0.05). Finally, the
SNp sensitivity was reduced [ED50 were 230 6 76 nmValues are expressed as mean 6 sem. Experimental
groups were compared using analysis of variance, paired and 109 6 44 nm for FK506 and control, respectively
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Table 1. Effect of short-term (8 days) FK506 treatment on the
plasma levels of creatinine, urea, total cholesterol, calcium and
magnesium, and on glomerular filtration rate (GFR)
(N 5 11 animals per group)
Variable Control FK506 P
Creatinine lm 6464 54 63 NS
Urea mm 6.460.4 8.0 60.3 ,0.001
Total cholesterol mm 1.5260.08 1.82 60.11 ,0.05
Calcium mm 2.360.02 2.2960.03 NS
Magnesium mm 0.5560.02 0.45 60.03 ,0.01
GFR ml/min/100 g body wt 1.160.2 1.2 60.1 NS
NS). After eight days of treatment, the body weight of
the animals receiving vehicle increased but did not
change significantly in the rats treated with FK506: body
weight gain was 19.8 6 3.3 and 23.5 6 3.1 g (P , 0.001)
for controls and FK506 animals. Baseline systolic blood
pressure also did not differ between the groups (130.7 6
4.4 vs. 132.6 6 3.4 mm Hg, P 5 NS). Post-treatment
systolic blood pressure was 132.2 6 3.7 and 137.1 6
3.1 mm Hg for vehicle and FK506, respectively. The
difference between pretreatment and post-treatment
blood pressure in the two groups was not significant:
4.50 6 2.6 mm Hg vs. 1.50 6 2.5 (P 5 NS).
Table 1 shows the effect of short-term FK506 treat-
ment on blood chemistry and on GFR. Compared with
vehicle, FK506 caused a significant increase in the plasma
levels of urea and total cholesterol and a reduction in
plasma magnesium concentrations. Plasma levels of cre-
atinine and calcium were not affected by FK506. When
plasma creatinine levels were corrected by body weight,
still no significant difference could be observed: 0.21 6
0.01 (control) vs. 0.18 6 0.01 (FK506, P 5 NS). There
was no difference in GFR between the groups. FK506
attained levels considered to be in the low therapeutic
trough range, as seen in patients receiving the drug
(5.95 6 0.96 ng/ml).
The arteries from animals treated with FK506 did not
show any significant alteration of their wall-to-lumen
ratio when compared with control: 0.0823 6 0.004 vs.
0.0894 6 0.006 for FK506 and control, respectively
(P 5 NS). However, departing from the results obtainedFig. 1. In vitro effect of FK506 on human arteries (N 5 7). Isolated
in the human and in the rat in vitro studies, resistancearteries were exposed for 24 hours with 1000 ng/ml FK506 (e) or
vehicle (d), contracted with norepinephrine (NE), and challenged with vessels of rats treated with FK506 presented a reduced
cumulative dose of acetylcholine (A) or sodium nitroprusside (B), as sensitivity to NE, as demonstrated by a shift of the dose–described in the Methods section. Asterisks indicate a significant (P ,
response curve to NE to the right (Fig. 2): NE-ED50 was0.05) difference between the two groups. SNp-ED50 values in controls
was 158 6 97 nm and in FK506 was 264 6 123 nm (P , 0.01). 2276 6 402 nm (FK506) and 1162 6 160 nm (control,
P , 0.05). The maximum response to the highest concen-
tration of NE employed was significantly reduced in the
FK506 group (Fig. 2). However, the calculated maximum(P , 0.01)]; however, no significant change in the maxi-
contraction to NE, taking into account all points of themum relaxation to SNp was observed (not shown).
dose–response curve, was not different from controls:
Protocol 2 5.8 6 0.2 vs. 5.6 6 0.3 mN/mm for controls and FK506,
respectively (P 5 NS). Maximum relaxation and sensitiv-Body weight was similar in both control and FK506
groups at baseline (316.1 6 5.3 vs. 313.5 6 7.9 g, P 5 ity to Ach were not impaired by FK506 in basal condi-
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tion in sensitivity to Ach, as evidenced by the reduced
fall in MAP following the infusion of low concentrations
of Ach (Fig. 6A). In contrast, a greater fall in blood
pressure was achieved in FK506 animals with higher
concentrations of Ach (same figure). At these Ach con-
centrations, animals receiving FK506 experienced a
blunted heart rate response compared with controls
(Fig. 6B).
Protocol 4
After 21 days of treatment, trough levels of FK506
were 3.64 6 0.05 ng/ml, still within the human therapeutic
range. Indirect systolic blood pressure was not different
from control: 155.1 6 4.3 mm Hg vs. 159.1 6 3.6 mm
Hg for FK506 and control, respectively (P 5 NS). During
the same period, animals treated with FK506 developed
a positive sodium balance contrary to the control animals
(2.11 6 0.23 mmol/day vs. 0.97 6 0.08 mmol/day, P ,
0.001). In spite of that, animals treated with FK506
gained only 6.7 6 8. g body wt, whereas controls rats
Fig. 2. Effect of FK506 (short-term treatment) on NE-induced contrac- gained 36.3 6 8.4 g during the experiment (P , 0.02).
tion in isolated rat arteries (ex vivo studies). Arteries isolated from
As can be seen in Table 2, FK506 caused a significantFK506-treated (e) and control (d) animals (N 5 11 per group) were
challenged with a cumulative dose of NE. Asterisks indicate a significant increase in plasma urea (P , 0.001). On the other hand,
(P , 0.05) difference between the two groups. plasma creatinine was not significantly changed. Plasma
magnesium concentration was reduced, and total choles-
terol was increased in animals treated with FK506.
The wall-to-lumen ratio of the mesenteric arteries wastions (Fig. 3A). However, preincubation of the vessels
not significantly changed by 21 days of FK506 treatment.
with l-arginine reduced the sensitivity to Ach in the
It was 0.108 6 0.003 for FK506 and 0.098 6 0.005 for
FK506 group: Ach-ED50 increased from 142 6 46 nm control (P 5 NS). In agreement with the results of the
(basal) to 290 6 72 nm (l-arginine, P , 0.05). No such short-term study, the sensitivity to NE was significantly
change was observed in control arteries exposed to reduced in the FK506 animals: 1023 6 85 versus 724 6
l-arginine: Ach-ED50 was 87 6 20 nm (basal) and 81 6 90 nm for FK506 and control, respectively (P , 0.02).
20 (l-arginine). Thus, after repletion with l-arginine, The maximum response to NE was similar in the two
FK506 arteries had a reduced sensitivity to Ach as com- groups: 5.13 6 0.24 (FK506) and 4.72 6 0.26 mN/mm
pared with controls (Fig. 3B). The response to SNp was (control, P 5 NS). Contrary to the short-term experi-
next investigated in order to test the endothelium-inde- ment, the maximum response to Ach was reduced by
pendent relaxation. Sensitivity to SNp was significantly FK506 (Fig. 7A). However, the sensitivity to Ach was
reduced with FK506, whereas the maximum relaxation preserved, similar to the results obtained in the short-
was not affected (Fig. 4). term protocol: 79 6 14 and 69 6 11 nm for control and
FK506, respectively (P 5 NS). Because Ach is known toProtocol 3
stimulate the release of thromboxane, a vasoconstrictor
After eight days of FK506 administration, MAP di- prostaglandin, we tested the hypothesis that the reduced
rectly measured in conscious animals was not different maximum-relaxation response was due to interference
from the controls (154.3 6 8.6 vs. 148 6 5.6 mm Hg, by that prostanoid. Preincubation of the resistance ves-
P 5 NS). However, there was a significant increase in sels of FK506 animals with indomethacin, a prostaglan-
heart rate (521 6 13 vs. 436 6 13, P , 0.001). The din synthesis inhibitor, did not restore maximum relax-
evaluation of pressor responsiveness to NE was coherent ation to normal (Fig. 7B). We then tested the hypothesis
with the results obtained in the ex vivo studies (protocol that the altered maximum Ach-induced relaxation was
2). The MAP dose–response curve was displaced signifi- the consequence of decreased production of nitric oxide
cantly to the right, configuring a reduction in the sensitiv- (NO). For this, we used methylene blue (MB), a NO
ity to NE (Fig. 4A). Maximum response to NE was not quencher [18]. The rationale for using MB was that ves-
affected (Fig. 5A). The heart rate response to NE was sels with decreased NO production would be less respon-
significantly attenuated in the rats receiving FK506 as sive to MB, thus suppressing the difference between con-
trol and FK506. As shown in Figure 7B, MB decreasedcompared with controls (Fig. 5B). FK506 caused a reduc-
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Fig. 3. Effect of FK506 (short-term treat-
ment) on Ach-induced relaxation in isolated
rat arteries (ex vivo studies). Arteries isolated
from FK506-treated (e) and control (d) ani-
mals (N 5 11 per group) were contracted with
NE and challenged with cumulative dose of
Ach. Relaxation to Ach was determined in
basal conditions (A) or after incubation with
l-arginine (B) (300 mm for 20 min). Asterisks
indicate a significant (P , 0.05) difference
between the two experimental groups.
DISCUSSION
We started this investigation exploring the hitherto
not reported direct effect of FK506 on the vasoconstric-
tor and vasodilator responses of human resistance vessels
in vitro, complemented with observations in the rat. We
considered this approach relevant because it freed us
from the interference of confusing factors operating in
the whole organism, and because the effects of FK506
on the cardiovascular system might vary in the different
species. In this work, human resistance vessels preincu-
bated for 24 hours with FK506 presented an increased
sensitivity to NE and moderate but significant alterations
in endothelium-dependent and -independent relaxation.
Similar alterations were observed in the rat vessels. The
increased response to NE may be ascribed to the direct
effect of FK506 on neurotransmitter release from adren-
ergic nerve terminals [19], but more likely is secondary
to a decrease in vasodilatory tone, as evidenced by the
compromised response to Ach and to SNp. It should
be emphasized that the concentrations of FK506 that
elicited these effects were well above of the trough levels
Fig. 4. Effect of FK506 (short-term treatment) on SNp-induced relax- achieved in patients, and that experiments conducted
ation in isolated rat arteries (ex vivo studies). Arteries isolated from with concentrations close to those considered clinicallyFK506-treated (e) and control (d) animals (N 5 11 per group) were
adequate did not elicit any change in vascular function.contracted with NE and challenged with cumulative dose of SNp. Aster-
isks indicate a significant (P , 0.05) difference between the two experi- That means that the vascular effects registered in vitro,
mental groups. although showing the potential vascular toxicity of
FK506, do not necessarily reflect these effects under
normal clinical situations. For that reason, we also ran
ex vivo and in vivo experiments in animals because toxi-the maximum response to Ach in both groups but did
cological studies in normal humans should not be accept-not suppress the difference between FK506 and controls.
able.We finally tested the response to exogenous NO using
We showed that animals treated with FK506 do notSNp. The results, presented in Figure 8, showed that
develop hypertension, either during the short- or long-FK506 impaired both sensitivity and maximum response
to SNp. term course of the drug. This was found by measuring
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Fig. 5. Effect of FK506 (short-term treatment) on blood pressure and
heart rate responsiveness to NE in the rat (in vivo studies). FK506-
treated (e) and control (d) animals (N 5 10/group) were instrumented Fig. 6. Effects of FK506 (short-term treatment) on blood pressure and
as described in the Methods section. Mean arterial pressure (MAP; A) heart rate responsiveness to Ach in the rat (in vivo studies). FK506-
and heart rate (B) responsiveness (peak response 2 baseline) was treated (e) and control (d) animals (N 5 10/group) were instrumented
determined after bolus injections of NE (Methods section). Asterisks as described in the Methods section. Blood pressure [mean arterial
indicate a significant (P , 0.05) difference between the two groups. pressure (MAP), A] and heart rate (B) responsiveness (peak response 2
baseline) were determined after a five-minute infusion of Ach (Methods
section). Asterisks indicate a significant (P , 0.05) difference between
the two groups.
blood pressure indirectly, as well as by the direct method,
in the conscious animal. The absence of a hypertensive
effect of FK506 occurred despite concomitant sodium
Table 2. Effect of long-term (21 days) FK506 treatment on theretention during the administration of the drug and with
plasma levels of creatinine, urea, total cholesterol, calcium and
blood levels within human therapeutic range [20]. These magnesium (N 5 9 animals per group)
concentrations have also been proved to be immunosup-
Variable Control FK506 P
pressive in the rat [21]. Significant elevation in blood
Creatinine mm 6764 6865 NSpressure with FK506 can, however, be achieved in the
Urea mm 5.360.3 8.460.6 ,0.001
rat with higher, intravenous doses of the drug [19]. These Total cholesterol mm 1.5160.08 2.4460.17 ,0.001
Calcium mm 2.4860.02 2.5760.02 NSfindings contrast with the observations that moderate
Magnesium mm 0.7060.02 0.5260.02 ,0.01doses of cyclosporine in the same model are usually
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Fig. 7. Effect of FK506 (long-term treat-
ment) on Ach-induced relaxation in isolated
rat arteries (ex vivo studies). (A) Arteries iso-
lated from FK506-treated (e) and control (d)
animals (N 5 9 per group) were contracted
with NE and challenged with a cumulative
dose of Ach in basal conditions (asterisks indi-
cate a significant difference between the two
groups). Relaxation to Ach was also con-
ducted after incubation with indomethacin or
with a mixture of indomethacin and methyl-
ene blue. The maximum responses to Ach (ex-
pressed as percentage of precontraction with
NE) in all three conditions are shown in (B).
Symbols are: ( ) control; (h) FK506-treated
animals.
these experiments. Studies by others have shown that
chronic administration of FK506 to rats under a low-salt
diet [17] and to mice under an unrestricted diet [25]
caused a reduction in renal function. If the same alter-
ation occurred in our long-term experiments, it could be
a plausible explanation for the sodium retention ob-
served in the FK506 group. The most interesting aspect
of our study is related to the functional observations in
the resistance vessels, as they help to explain the reduced
hypertensive properties of FK506 when compared with
cyclosporine. In the short-term animal experiments, we
found that resistance vessels of rats exposed to FK506
presented a reduced sensitivity to NE, preservation of
the endothelium-dependent relaxation, and compro-
mised endothelium-independent relaxation. A likely ex-
planation for the reduced response to NE is that stimula-
tion of sympathetic nervous system over one week or
more could have induced the desensitization to the ago-
nist. In this regard, Lyson et al showed that FK506 acti-
vates renal sympathetic nerves, a characteristic alsoFig. 8. Effect of FK506 (long-term treatment) on SNp-induced relax-
ation in isolated rat arteries (ex vivo studies). Arteries isolated from shared with cyclosporine [19]. The fact that both drugs
FK506-treated (e) and control (d) animals (N 5 9 per group) were reduced NE sensitivity [13] reinforces this argument. The
contracted with NE and challenged with cumulative dose of SNp. Aster-
preservation of the endothelium-dependent relaxationisks indicate a significant (P , 0.05) difference between the two experi-
mental groups. (response to Ach) in the short-term experiments is, how-
ever, remarkable because it establishes a clear contrast
with previous data demonstrating the adverse effect of
cyclosporine on endothelial function [13, 26–28] and sug-associated with a sustained and significant increase in
gests that FK506 does not impair NO synthesis or release.blood pressure [13, 22].
Interestingly, the incubation of the resistance vesselsFK506 did not change plasma creatinine or GFR
with l-arginine, the NO synthase substrate, caused a(short-term study). This is in agreement with investiga-
significant reduction in Ach sensitivity in the rats treatedtions showing the lack of acute effect of FK506 on GFR,
with FK506 but not in controls. This suggests that therenal vascular resistance, and renal plasma flow in the
FK506 vessels might have produced more NO by com-rat [23, 24]. On the other hand, a mild reduction in renal
parison with controls during the incubation with l-argi-function in the animals exposed 21 days to the drug
cannot be excluded because GFR was not measured in nine and become desensitized to the endothelial NO
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released upon Ach addition. Saturation of vascular the data indicate that a more prolonged administration
of FK506 may produce pathologic alterations in the en-smooth muscle cell with excess NO may have also caused
the reduction in SNp sensitivity observed in all our exper- dothelium, the smooth muscle cell, or both. The fact that
the maximum relaxation could not be achieved eitheriments and may have interfered with NE responsiveness,
as reported previously [29–31]. It is tempting to specu- with Ach or SNp, however, points to a predominant
late, at this point, that FK506 exerts a proinflammatory defect in the smooth muscle cell rather than in the endo-
stimulus on the arteries and stimulates the expression of thelium. Moreover, the failure for MB exposure to influ-
inducible NO synthase. Future experiments measuring ence the response to Ach also suggests a more significant
both the expression and the activity of this enzyme in impairment of the smooth muscle. Finally, the reduction
arteries or cultured vascular smooth muscle cells will be in the maximum relaxation apparently was not related
necessary to confirm this hypothesis. to stimulation of endothelial thromboxane synthesis by
Our short-term study on blood pressure respon- Ach, as it was not reversed by indomethacin. In this
siveness supports in part the conclusions of our vascular regard, the absence of stimulatory effect of FK506 on the
reactivity experiments discussed earlier here. First, rats thromboxane pathway further contrasts with the effect
treated with FK506 presented significant tachycardia at of cyclosporine A, as noted by Benigni et al in their
the baseline period compared with controls, despite simi- experiments with bovine aortic endothelial cells in cul-
lar levels of MAP. This strongly suggests that blood ture [24].
pressure was maintained by reflex increase in cardiac The mechanism of smooth muscle injury secondary to
output in response to systemic vasodilation. Also, the FK506 treatment can only be speculated at this time. It
rats receiving FK506 presented a reduced pressor re- is tempting though to propose that impaired vascular
sponsiveness to exogenous NE, suggesting a possible reactivity is a manifestation of drug-induced inflamma-
activation of the sympathetic nervous system with sec- tion of the arterial wall and that excess inflammatory
ondary desensitization of adrenergic receptors as postu- NO produced in response to the drug is the primary cause
lated in our ex vivo experiments. Experiments assessing of cellular damage as postulated for certain glomerular
sympathetic nervous system activity by the measurement diseases [33]. Interestingly, magnesium deficiency itself
of arterial NE levels, nerve traffic, or receptor expression is capable of stimulating the production of inflammatory
will have to be undertaken to give further support to NO [34]. In this context, enhanced NO production fol-
this hypothesis. lowing FK506 treatment could be the consequence of a
The activation of the sympathetic nervous system direct activation of inducible NO synthase by the drug
would also explain impaired MAP reactivity to the low- or be secondary to drug-induced magnesium depletion
est doses of Ach employed (Fig. 6A). Surprisingly, and (Tables 1 and 2). Further investigations will be necessary
in apparent contrast with our ex vivo findings, higher to test each of these hypotheses.
doses of Ach in FK506-treated animals caused a signifi- In conclusion, we provide experimental evidence of
cantly larger fall in MAP in comparison with the controls, the progressive nature of the vascular functional alter-
and this effect was associated with a blunted heart rate ations associated with the use of FK506. These alter-
response to the fall in blood pressure. We interpret these ations differ from those observed with cyclosporine
data as another manifestation of FK506-induced periph- in being less pronounced and affecting predominantly
eral vasodilation. Thus, in our animals, similar to what the smooth muscle. The vascular changes are not associ-
is observed in hemorrhagic [30] or septic [32] shock, ated with hypertension, but rather, with hemodynamic
blood pressure would tend to fall and is barely main- changes consistent with excess peripheral vasodilation.
tained within normal range by sympathetic nervous sys- The alteration of both endothelium-dependent and
tem activation. Systemic challenge with high doses of -independent relaxation observed after long-term expo-
Ach might have overcome this regulation and revealed sure to FK506 suggests, however, that the vascular mani-
the underlying vasodilation. In vivo experiments with festations of the drug toxicity may represent the forerun-
selective adrenergic antagonists or NO synthase inhibi- ner of hypertension and other alterations seen with more
tors may be useful in the future to confirm this hypoth- prolonged use of the drug in the transplant population.
esis.
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